Immunovant (IMVT) Long-Term Debt Issuances (2019 - 2021)

Immunovant (IMVT) has 3 years of Long-Term Debt Issuances data on file, last reported at -$3.2 million in Q1 2021.

• Quarterly Long-Term Debt Issuances fell 111.77% year-over-year to -$3.2 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was -$3.2 million (down 110.53% YoY) and the FY2020 annual result came in at $35.0 million, changed N/A from the prior year.
• Long-Term Debt Issuances eased to -$3.2 million in Q1 2021, from $134000.0 in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $27.1 million in Q1 2020 to a low of -$27.1 million in Q4 2019.
• A 3-year average of $662500.0 and a median of $251000.0 in 2019 frame the typical range for Long-Term Debt Issuances.
• Annual changes were most pronounced in 2020 — Long-Term Debt Issuances soared 100.49% — and 2021, when it tumbled 111.77%.
• Tracing IMVT's Long-Term Debt Issuances over 3 years: stood at -$27.1 million in 2019, then soared by 100.49% to $134000.0 in 2020, then slumped by 2480.6% to -$3.2 million in 2021.
• The last three Long-Term Debt Issuances figures came in at -$3.2 million (Q1 2021), $134000.0 (Q4 2020), and $202000.0 (Q3 2020), per Business Quant data.